Search results
Showing results for
Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.
Gisela Robles Aguilar
Gisela Robles Aguilar - Global Burden of Disease Researcher
Rachel Hounsell
Rachel Hounsell - Senior Researcher and Teaching Fellow
Proochista Ariana
- MSc IHTM Executive Team
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Kevin Marsh
Kevin Marsh - Professor of Tropical Medicine
Marco Liverani
Marco Liverani - Honorary Visiting Research Fellow in Tropical Medicine
Philippe Guérin
Philippe Guérin - Professor of Epidemiology and Global Health
Christiane Dolecek
MD PHD FRCP Christiane Dolecek - Professor of Global Health
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
Phaik Yeong Cheah
Phaik Yeong Cheah - Professor of Global Health
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Bridget Wills
Bridget Wills - Professor of Tropical Medicine